<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971825</url>
  </required_header>
  <id_info>
    <org_study_id>CC-92252-CP-001</org_study_id>
    <secondary_id>U1111-1229-5867</secondary_id>
    <secondary_id>2018-001050-10</secondary_id>
    <nct_id>NCT03971825</nct_id>
  </id_info>
  <brief_title>A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis</brief_title>
  <official_title>A Phase 1, Randomized, 3-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, single-center, 3-part, study to assess the safety,&#xD;
      tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects&#xD;
      and multiple doses of CC-92252 in adult subjects with psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Did not meet progression criteria&#xD;
  </why_stopped>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Actual">August 5, 2021</completion_date>
  <primary_completion_date type="Actual">August 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From enrollment until at least 28 days after completion of study treatment</time_frame>
    <description>Number of participants with adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Observed maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-t</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Area under the serum concentration-time curve calculated from time zero to the last measured time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-∞</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2z</measure>
    <time_frame>UP to 16 weeks</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL/F</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Apparent clearance of drug from serum after subcutaneous dosing administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>clearance of drug from serum after IV dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vz/F</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Apparent volume of distribution during the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vz</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Apparent volume of distribution during the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody Immunogenicity Anti-drug antibody</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Evaluation of anti-CC-92252 antibody formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pharmacodynamic biomarkers</measure>
    <time_frame>UP to 24 weeks</time_frame>
    <description>Change in lymphocyte counts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Administration of CC-92252 and Placebo in Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of CC-92252 and Placebo in Psoriasis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-92252</intervention_name>
    <description>CC-92252</description>
    <arm_group_label>Administration of CC-92252 and Placebo in Healthy Subjects</arm_group_label>
    <arm_group_label>Administration of CC-92252 and Placebo in Psoriasis subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Administration of CC-92252 and Placebo in Healthy Subjects</arm_group_label>
    <arm_group_label>Administration of CC-92252 and Placebo in Psoriasis subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
        Part 1, Part 2, and Part 3&#xD;
&#xD;
          1. Subject is ≥ 18 and ≤ 55 years (Part 1 and Part 2) and age is ≥ 18 and ≤ 60 years&#xD;
             (Part 3) of age at the time of signing the ICF.&#xD;
&#xD;
          2. Subject has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures&#xD;
&#xD;
          3. Subject has a body mass index (BMI) ≥ 18 and ≤ 30 kg/m2 (Part 1 and Part 2) and BMI ≥&#xD;
             18 and ≤ 33 kg/m2 (Part 3), at screening.&#xD;
&#xD;
          4. Subject has clinical laboratory safety test results that are within normal limits or&#xD;
             considered not clinically significant by the Investigator.&#xD;
&#xD;
             Applicable to Part 3 only&#xD;
&#xD;
          5. Subject has a clinical diagnosis of stable plaque-type PsO at least 6 months prior to&#xD;
             screening, defined as:&#xD;
&#xD;
             BSA ≥ 5% (at both screening and baseline), and sPGA score ≥ 3 (at both screening and&#xD;
             baseline)&#xD;
&#xD;
          6. Must have at least two plaques, at least 3 x 3 centimeters (cm) in diameter. One&#xD;
             plaque will be used for punch biopsy and the other for Target Plaque Severity Score&#xD;
             (TPSS) evaluation.&#xD;
&#xD;
          7. Must be in generally good health (except for PsO) as judged by the Investigator&#xD;
&#xD;
          8. No prior exposure to systemic treatments or biologics for the treatment of psoriasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a subject from enrollment:&#xD;
&#xD;
        Part 1, Part 2, and Part 3&#xD;
&#xD;
          1. Subject has any significant medical condition that would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
             a. Part 3 only: This exclusion does not apply to plaque psoriasis&#xD;
&#xD;
          2. History or presence of cancer&#xD;
&#xD;
          3. Presence of pre-cancerous conditions&#xD;
&#xD;
          4. History or presence of a systemic infection or any potentially opportunistic&#xD;
             infections&#xD;
&#xD;
          5. Subject has any condition, including the presence of laboratory abnormalities, which&#xD;
             places the subject at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
          6. Subject has any condition that confounds the ability to interpret data from the study&#xD;
&#xD;
          7. Subject is pregnant or breastfeeding&#xD;
&#xD;
          8. Part 1 and Part 2 only: Subject was exposed to an investigational drug (new chemical&#xD;
             entity) within 30 days preceding the first dose administration, or 5 half-lives of&#xD;
             that investigational drug, if known (whichever is longer)&#xD;
&#xD;
          9. Part 1 and Part 2 only: Subject has used any prescribed systemic or topical medication&#xD;
             within 30 days prior to the first dose administration.&#xD;
&#xD;
         10. Part 1 and Part 2 only: Subject has used any non-prescribed systemic or topical&#xD;
             medication within 14 days prior to the first dose administration. Exceptions may apply&#xD;
             on a case-by-case basis if considered not to interfere with the study objectives as&#xD;
             agreed to and documented by the Investigator and Sponsor's Medical Monitor.&#xD;
&#xD;
         11. Subject has a history of drug abuse (as defined by the current version of the&#xD;
             Diagnostic and Statistical Manual [DSM]) within 2 years before the first dose&#xD;
             administration, or positive drug screening test reflecting consumption of illicit&#xD;
             drugs&#xD;
&#xD;
         12. Subject has a history of alcohol abuse (as defined by the current version of the DSM)&#xD;
             within 2 years before the first dose administration, or positive alcohol screen&#xD;
&#xD;
         13. Subject is known to have a history of hepatitis B and/or hepatitis C, or have a&#xD;
             positive result to the test for human immunodeficiency virus (HIV) antibodies at&#xD;
             screening Note: Subjects who received hepatitis B vaccination and who test positive&#xD;
             for hepatitis B surface antibody and negative for both hepatitis B surface antigen and&#xD;
             hepatitis B core antibody remain eligible for study participation&#xD;
&#xD;
         14. Subject smokes &gt; 10 cigarettes per day, or the equivalent in other tobacco products&#xD;
             (self-reported)&#xD;
&#xD;
         15. Vaccination within 30 days prior to the first dose administration or subject has plans&#xD;
             to receive a vaccination during the course of the study&#xD;
&#xD;
         16. Subject has received immunization with a live or live attenuated vaccine within 2&#xD;
             months prior to the first dose administration or is planning to receive immunization&#xD;
             with a live or live attenuated vaccine for 2 months following the last dose&#xD;
             administration&#xD;
&#xD;
         17. Subject has a positive QuantiFERON®-TB Gold (or equivalent) TB test at screening or 2&#xD;
             successive indeterminate QuantiFERON®-TB Gold (or equivalent) TB tests at screening&#xD;
&#xD;
         18. Subject has a history of incompletely treated Mycobacterium tuberculosis (TB)&#xD;
             infection&#xD;
&#xD;
         19. Topical therapy within 2 weeks of randomization (including, but not limited to,&#xD;
             topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus,&#xD;
             pimecrolimus, or anthralin/dithranol). Use of phototherapy within 4 weeks prior to&#xD;
             first dose administration.&#xD;
&#xD;
         20. Prolonged sun exposure or use of tanning booths Applicable to Part 3 only&#xD;
&#xD;
         21. Presence of non-plaque psoriasis&#xD;
&#xD;
         22. Subject has psoriasis flare within 4 weeks before screening&#xD;
&#xD;
         23. Presence of dermatological diseases other than plaque psoriasis&#xD;
&#xD;
         24. Presence of Psoriatic Arthritis&#xD;
&#xD;
         25. Use of topical therapy for psoriasis within 14 days of first dosing (including but not&#xD;
             limited to corticosteroids, retinoids, vitamin D analog, calcineurin inhibitors,&#xD;
             salicylic acid) Exceptions: low potency topical corticosteroids will be allowed as&#xD;
             background therapy for treatment of psoriatic lesions of the face, axillae and groin&#xD;
             in accordance with the manufacturers' suggested usage; subjects with scalp psoriasis&#xD;
             will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on&#xD;
             scalp lesions; Eucerin® cream (the standard emollient for this study; or equivalent)&#xD;
             will also be permitted for body lesions only. Subjects must not use these treatments&#xD;
             within 24 hours prior to each clinic visit.&#xD;
&#xD;
         26. Use of systemic therapy for psoriasis within 30 days of first dose administration&#xD;
&#xD;
         27. Use of phototherapy for psoriasis within 30 days of first dose administration&#xD;
&#xD;
         28. Use of systemic biologic treatment within 24 weeks of first dose administration&#xD;
&#xD;
         29. Exposure to an immunosuppressive or immunomodulatory drug within 30 days of first dose&#xD;
             administration, or five half-lives of the drug (whichever is longer)&#xD;
&#xD;
         30. Exposure to an investigational drug (new chemical entity) within 30 days preceding the&#xD;
             first dose administration, or five half-lives of that investigational drug, if known&#xD;
             (whichever is longer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Ramirez-Valle, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Safety</keyword>
  <keyword>CC-92252</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

